Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities

NACompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

June 27, 2024

Study Completion Date

June 27, 2024

Conditions
Breast Abnormalities
Interventions
OTHER

Contrast Enhanced Spectral Mammography (CESM)

Women presenting to MSKCC with a palpable abnormality within the breast either self palpated \& or palpated by their physician will be offered CESM instead of FFDM alone. The breast imager assigned to care for the patient will interpret the low energy images (including any additional views they routinely obtain) \& record their findings. They will then interpret the CESM \& record those results. As per standard of care, the patient will have a targeted ultrasound as well. Appropriate clinical recommendations will be made. In patients with no specific imaging findings, follow-up will be determined by the degree of suspicion of the palpable finding \& will either be called negative \& followed clinically if not suspicious, or will go on to MRI , percutaneous biopsy by a surgeon or surgical biopsy if suspicious.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02406274 - Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities | Biotech Hunter | Biotech Hunter